Q2 FY2026 · ended Jun 30, 2026 · Revenue $6.09M, +267.6% YoY · Filed Aug 13, 2026
Alpha Cognition Inc. (ACOG) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $6.1 million and a net loss of $8.8 million. Free cash flow was -$7.0 million.
Revenue
$6.09M
+267.6% vs year-ago quarter
Net income
$-8.79M
+33.4% vs year-ago quarter
Operating cash flow
$-6.86M
-11.7% vs year-ago quarter
Free cash flow
$-6.96M
-13.2% vs year-ago quarter
EPS
$-0.40
+51.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
21.78M
+34.8% vs year-ago quarter
Net cash
—
Operating margin
-174.7%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ACOG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Grapevine, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1655923
- Former names
- Neurodyn Cognition Inc. (until Oct 9, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $6.1M | $3.5M | $2.8M | $2.8M | $1.7M |
| Operating income | -$7.8M | -$8.1M | -$7.9M | -$5.3M | -$8.4M |
| Net income | -$8.8M | -$6.5M | -$6.9M | -$1.3M | -$13.2M |
| Diluted EPS | -$0.40 | -$0.32 | -$0.30 | -$0.30 | -$0.82 |
| Operating cash flow | -$6.9M | -$11.8M | -$6.9M | -$5.3M | -$6.1M |
| Free cash flow | -$7.0M | -$11.8M | -$7.1M | -$5.4M | -$6.1M |
| Total assets | $64.5M | $69.2M | $79.7M | $46.3M | $45.1M |
| Total liabilities | $11.6M | $11.8M | $17.2M | $12.4M | $13.2M |
| Stockholders' equity | $53.0M | $57.5M | $62.5M | $33.9M | $26.7M |
| Cash and investments | $41.4M | $54.2M | $66.0M | $35.4M | $39.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 16, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
May 1, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 20, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Material agreement
|
Apr 14, 2026 | Apr 10, 2026 |
All 216 Alpha Cognition Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.